Each week we highlight five things affecting the life sciences industry. Here’s the latest.
UK biotech secures major late‑stage funding to advance oncology program
- Cambridge‑based biotechnology company CellCentric announced a $220 million financing round to advance development of its first‑in‑class, oral cancer drug, reports BioSpace.
- The funding round is the largest private biotech financing in Europe so far in 2026, reflecting investors’ renewed willingness to back late‑stage, data‑rich oncology assets while still deploying capital selectively in the biotech market.
$2.2 billion acquisition of an autoimmune company announced
- A large multinational biopharmaceutical company agreed to acquire an autoimmune-focused startup company for up to $2.2 billion, expanding its autoimmune portfolio with bispecific antibody and T‑cell engager therapies designed to “reset” the immune system rather than broadly suppress it.
- According to Biopharma Dive, the deal highlights growing pharma interest in bispecifics sourced from China‑licensed assets, as the startup’s pipeline originates from Chinese biotech partnerships and reflects a broader industry trend toward global licensing and mergers and acquisitions to access next‑generation autoimmune treatments more efficiently.
FDA warns of ongoing shortages of neurosurgical supplies
- Patties, sponges and strips are among the items listed as supply shortages by the U.S. Food and Drug Administration; it cautioned that disruptions are expected to continue through at least the end of 2026 due to supplier issues.
- According to Medtech Dive, the shortage is largely driven by a major medical supply company recall after elevated endotoxin levels were found in neuro sponge products. The FDA is urging providers to conserve supply, use alternatives where possible, diversify sourcing and report any related supply chain challenges or adverse events.
FDA launches a one-day inspectional assessment pilot program
- The FDA’s recently launched one-day inspectional assessment pilot program is to supplement traditional facility inspections aiming to deploy inspection resources more efficiently by conducting shorter, risk‑focused reviews, often targeted using artificial intelligence‑driven risk analytics across biologics, medical products, clinical research programs and food facilities.
- The one‑day assessments are a screening tool, not a replacement for full inspections, and can be expanded if issues are identified. The pilot will run through the end of the year as the FDA evaluates whether it improves oversight effectiveness and helps address inspection backlogs, reports Fierce Pharma.
Big Pharma moving from AI experimentation to measurable execution
- Many of the large pharmaceutical companies are demonstrating tangible gains across discovery, clinical development, manufacturing and commercial operations, including materially faster target identification, molecule design and clinical cycle times, as reported within their earnings presentations, according to Fierce Biotech.
- AI is increasingly shaping business development and mergers and acquisitions strategy as pharma companies use advanced analytics to identify overlooked pipeline value, improve deal diligence, and guide acquisition and partnership decisions, positioning AI as a core driver of both innovation and capital allocation.
For more insights in life sciences, check out RSM’s industry outlook.
